Showing 151-160 of 5121 results for "".
Journal Club: How Physicians Can Use the New AD Guidelines in Practice
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/how-physicians-can-use-the-new-ad-guidelines-in-practice/24094/In this second part of the inaugural edition of Practical Dermatology's® Atopic Dermatitis (AD) Journal Club, Derek Chu, MD, a key architect of new guidelines for AD management and care, talks with Peter Lio, MD, about his vision for how to make these guidelines easy-to-use and practical for dermatoLive in Las Vegas: Get Ready for DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/live-in-las-vegas-get-ready-for-derm2021/19968/The DERM2021 NP/PA CME Conference offers dermatology physician assistants and nurse practitioners an opportunity to stay up to date on the latest products, drugs, and treatments in dermatology to improve care for patients. Joe Gorelick, MSN, FNP-BC, DEF President, says this year’s conference is goinDERM2020 Content Recap: Brad Glick, DO, MPH
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-brad-glick-do/19840/DERM2020 Faculty Brad Glick, DO, MPH shares his thoughts on DERM2020 and some of the presentations around COVID.Evaluating GEP Test Options
https://practicaldermatology.com/programs/practical-dermatology/evaluating-gep-test-options/35600/David Cotter, MD, a board-certified dermatologist, discusses what he looks for in a gene expression profile (GEP) test, including the types of clinical evidence that are most important.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuDermWireTV: Latest on Galderma, Eczema Awareness, Hacking Derm, and More
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-latest-on-galderma-eczema-awareness-hacking-derm-and-more/19675/In this week’s edition: Galderma’s Aklief (trifarotene) topical cream is now approved for acne. Sandra Johnson, MD weighs in. Supported by Sanofi and Regeneron in partnership with the National Eczema Association, the Understand AD Squad includes dermatologist Mercedes Gonzalez, MD, who discusses herGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dDERM2020 Content Recap: Linda Stein Gold, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-linda-stein-gold-md/19845/DERM2020 Faculty Linda Stein Gold, MD discusses what’s new in acne from her presentation during DERM2020.Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse and